Dr. Michael H. Rivner, MD

Dr. Rivner practices at Wellstar MCG Health Medical Center in Augusta, Georgia, part of Wellstar Health System.

Dr. Rivner's NPI, 1669582649, was assigned on August 30, 2006. Dr. Rivner graduated from Duke University School of Medicine in 1978. Dr. Rivner holds Georgia license 020806.

Dr. Rivner's primary practice is Wellstar MCG Health Medical Center, at 1120 15th Street, Augusta, GA 30912 in Richmond County. The practice phone is (706) 721-6569.

Dr. Rivner's primary practice is Wellstar MCG Health Medical Center in Augusta, Georgia, part of Wellstar Health System. Dr. Rivner is also affiliated with Atrium Health Navicent Rehabilitation Hospital. The medical group on file is Wellstar Medical Group. Dmand AI also links Dr. Rivner to 3 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rivner practices, 4 sites in all. Vendor and product names are available with a free account.

Clinical neurophysiology is Dr. Rivner's primary specialty in the NPI Registry, under taxonomy code 2084N0600X. Dr. Rivner is licensed in Georgia.

CMS data shows 464 Medicare services from Dr. Rivner across 9 procedure codes in 2024, for 168 Medicare patients. Medicare paid $30,770 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 168 Medicare patients who saw Dr. Rivner in 2024. The largest group is 65 to 74, with 65 patients. 73% of them have high blood pressure, and 69% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rivner's median patient age at 69, with 54% women.

In 2024, Dr. Rivner wrote 1,598 Medicare Part D claims for 181 patients. 65% of them were for generic drugs. CMS names the drug for 1,327 of them, across 32 drugs with 11 or more claims each, at $8,972,056 in total drug cost. In 2023, CMS named 1,413 claims across 37 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Rivner for performance year 2024, reported through an alternative payment model (APM). Dr. Rivner accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rivner as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 18 papers to Dr. Rivner, published from 2013 to 2024. 2020 was the busiest year, with 3. The most frequent topics are Amyotrophic Lateral Sclerosis, Autoantibodies and Myasthenia Gravis. Dr. Rivner has published most often in Muscle Nerve. Dr. Rivner's most frequent co-authors are Lin Mei, MD, Namita A. Goyal, MD and Stephen Aaron Goutman, MD.

Dmand AI links Dr. Rivner to 5 clinical trials, 3 of them phase 2 studies. Conditions studied include Myasthenia Gravis, Neuromuscular Junction Diseases and Amyotrophic Lateral Sclerosis. Grifols Therapeutics LLC sponsors the most, 2. Open Payments lists research payments to Dr. Rivner that name 1 trial.

CMS Open Payments shows 619 general payments to Dr. Rivner from 39 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 79% of the total. Alexion Pharmaceuticals, Inc. paid the most, $114,460. It also lists 5 research payments totaling $3,878 from 2019 to 2022, naming 1 clinical trial.

Dr. Rivner graduated from Duke University School of Medicine in 1978.